Cargando…
A Pilot Microbiota Study in Parkinson’s Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models
BACKGROUND: Parkinson’s disease (PD) and multiple system atrophy (MSA) patients often suffer from gastrointestinal (GI) dysfunction and GI dysbiosis (microbial imbalance). GI dysfunction also occurs in mouse models of PD and MSA. OBJECTIVES: To assess gut dysfunction and dysbiosis in PD subjects as...
Autores principales: | Vidal-Martinez, Guadalupe, Chin, Brandon, Camarillo, Cynthia, Herrera, Gloria V., Yang, Barbara, Sarosiek, Irene, Perez, Ruth G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029363/ https://www.ncbi.nlm.nih.gov/pubmed/31561385 http://dx.doi.org/10.3233/JPD-191693 |
Ejemplares similares
-
FTY720-derivatives do not induce FTY720-like lymphopenia
por: Segura-Ulate, Ismael, et al.
Publicado: (2017) -
Preclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-Mitoxy
por: Enoru, Julius O., et al.
Publicado: (2016) -
FTY720 attenuates excitotoxicity and neuroinflammation
por: Cipriani, Raffaela, et al.
Publicado: (2015) -
New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth
por: Alshaker, Heba, et al.
Publicado: (2017) -
The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod
por: Patmanathan, Sathya Narayanan, et al.
Publicado: (2015)